Woodford bails on Sanofi while betting on biotech; GSK dishes on new U.S. R&D hub;

@FierceBiotech: Turns out drugmakers don't tell the whole truth about FDA rejections. More | Follow @FierceBiotech

@JohnCFierce: This will be a biotech to watch: Unum hits the gas on next-gen CAR-T tech after banking $65M round. Story | Follow @JohnCFierce

@DamianFierce: Listen to two arguably well-informed people talk about the week in biopharma. FierceBiotech Radio | Follow @DamianFierce

> U.K. biopharma investor Neil Woodford has dumped his stake in Sanofi ($SNY) and redoubled his bets on emerging biotech companies around Europe. News

> GlaxoSmithKline ($GSK), in the process of consolidating much of its U.S. R&D division, offered a glimpse at a planned research hub in Pennsylvania. Story

> Alnylam's ($ALNY) RNAi treatment for autoimmune disorders successfully silenced its target by as much as 96% in a study on 12 healthy volunteers. The company plans to move the candidate into a trial on the rare paroxysmal nocturnal hemoglobinuria by the end of the year. More

Medical Device News

@FierceMedDev: Illumina teams up with Chinese genomics firm for noninvasive prenatal test development. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Boston Scientific touts improved spinal cord stimulator at neuromodulation conference. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: FDA slaps Insulet with warning letter over insulin pumps. Article | Follow @EmilyWFierce

> Boston Scientific touts improved spinal cord stimulator at neuromodulation conference. Story

> Philips cautions on cardio mortality after ResMed sleep apnea data, intros cardiac imaging tool. Article

Pharma News

@FiercePharma: AB Science struggles to break out as canine cancer drug flounders. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Mylan recalls more injected cancer drugs it made for #Pfizer at its Agila plants in India. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Big Data study flags 'fairly compelling' link between stomach blockbusters and heart risks. Report | Follow @CarlyHFierce

> GSK deal keeps paying off for Novartis with more positive Arzerra data. Story

> Prisoners accuse Massachusetts of barring them from pricey hep C meds. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.